Celgene Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for CELGENE, and what generic alternatives to CELGENE drugs are available?
CELGENE has five approved drugs.
There are twenty-six US patents protecting CELGENE drugs.
There are five hundred and thirty-eight patent family members on CELGENE drugs in fifty countries and forty-one supplementary protection certificates in seventeen countries.
Summary for Celgene
| International Patents: | 538 |
| US Patents: | 26 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
| Patent Litigation for Celgene: | See patent lawsuits for Celgene |
| PTAB Cases with Celgene as patent owner: | See PTAB cases with Celgene as patent owner |
Drugs and US Patents for Celgene
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-004 | Feb 8, 2013 | RX | Yes | Yes | 9,993,467*PED | See Plans and Pricing | Y | See Plans and Pricing | |||
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-001 | Mar 25, 2020 | RX | Yes | No | 9,382,217 | See Plans and Pricing | See Plans and Pricing | ||||
| Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-004 | Jun 29, 2006 | AB | RX | Yes | Yes | 7,465,800 | See Plans and Pricing | Y | Y | See Plans and Pricing | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Celgene
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-003 | Feb 8, 2013 | 6,315,720 | See Plans and Pricing |
| Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-006 | Jun 5, 2013 | 6,045,501 | See Plans and Pricing |
| Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-001 | Feb 8, 2013 | 8,626,531 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CELGENE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 10 mg/vial | ➤ Subscribe | 2013-11-05 |
| ➤ Subscribe | Capsules | 1 mg, 2 mg, 3 mg and 4 mg | ➤ Subscribe | 2017-02-08 |
| ➤ Subscribe | Capsules | 5 mg, 10 mg and 15 mg | ➤ Subscribe | 2010-08-30 |
| ➤ Subscribe | Capsules | 50 mg and 100 mg | ➤ Subscribe | 2006-12-18 |
| ➤ Subscribe | Capsules | 150 mg | ➤ Subscribe | 2014-02-03 |
| ➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2010-07-12 |
| ➤ Subscribe | Capsules | 2.5 mg and 20 mg | ➤ Subscribe | 2016-07-12 |
| ➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2006-09-25 |
International Patents for Celgene Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovenia | 2291080 | See Plans and Pricing |
| Eurasian Patent Organization | 024801 | See Plans and Pricing |
| Denmark | 2105135 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Celgene Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2913326 | C20200031 00353 | Estonia | See Plans and Pricing | PRODUCT NAME: OSANIMOOD;REG NO/DATE: EU/1/20/1442 25.05.2020 |
| 2291080 | 2020/042 | Ireland | See Plans and Pricing | PRODUCT NAME: OZANIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR OZANIMOD HYDROCHLORIDE.; REGISTRATION NO/DATE: EU/1/20/1442 20200525 |
| 2291080 | CA 2020 00047 | Denmark | See Plans and Pricing | PRODUCT NAME: OZANIMOD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER OZANIMODHYDROCHLORID; REG. NO/DATE: EU/1/20/1442 20200520 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
